PATIENT SELECTION METHOD FOR ULTRASOUND HEMIABLATION OF LOCALIZED PROSTATE CANCER Russian patent published in 2019 - IPC A61N7/02 A61B10/02 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to oncourology, and can be used for the selection of patients for ultrasound hemiablation of localized prostate cancer. Perineal polyfocal biopsy of the prostate gland, multiparameter magnetic resonance imaging are performed. Additionally, a study of the initial level of prostate-specific antigen is performed. Perineal biopsy of the prostate gland is performed with a sampling of at least 24 biopsy samples. Tumor immunohistochemical profile is determined. Ultrasonic hemiablation is considered as justified if an initial level of prostate-specific antigen of no more than 10 ng/ml, the presence of unifocal, unilateral lesions of the prostate gland according to the data of multiparametric magnetic resonance imaging and histological examination data: the Gleason index is not more than 6, the absence of perineural invasion, the percentage of lesions within the biopsy is no more than 50 %, Grade 1–2, and with absolute values of the apoptosis marker p53 – 50 %, and proliferative activity of Ki-67 – 70 %.

EFFECT: method provides the possibility and efficiency of performing ultrasound hemiablation of localized forms of prostate cancer by creating selection criteria for patients with this pathology.

1 cl, 1 ex